Analytical Challenges in the Characterisation of Therapeutic Oligonucleotides

Designing an Oligonucleotide Quality Control Strategy

Designing a pertinent quality control strategy for oligonucleotides presents many challenges driven by the complexity of structure and absence of dedicated regulatory guidance. This presentation from Ashleigh Wake, Director of Biological Services at Intertek Pharmaceutical Services, discusses the design of a comprehensive characterisation program as well as discussing strategy to support for long term quality control, providing detail on the extensive analytics required as well as the relevance of each data set.

Please complete the form to access the presentation.